GLPwatch
Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.
Cureus · 2025
Last updated 2026-05-28The abstract reports that two GLP-1 drugs, semaglutide and tirzepatide, may cause unusual nerve-related symptoms like allodynia (pain from non-painful stimuli) and dysesthesia (abnormal sensations). These side effects can occur in people taking the drugs for either type 2 diabetes or weight management, seem to depend on the dose, and typically go away when the medication is stopped or sometimes on its own within weeks.
AI summary of the abstract below.
| Journal | Cureus, 2025 |
|---|---|
| Citations | 1 |
| Molecules | semaglutide, tirzepatide |
Abstract
Semaglutide and tirzepatide are two commonly prescribed glucagon-like peptide-1 (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonists used for the treatment of type 2 diabetes and chronic weight management. Allodynia and dysesthesia have been previously reported as effects of semaglutide. This case report adds to the literature on dysesthesia from semaglutide and presents a novel report in a patient taking tirzepatide. This adverse drug reaction occurs in both patients treated for type 2 diabetes and chronic weight management, appears to be dose dependent, and resolves with discontinuation of the drug and may resolve spontaneously after several weeks.
Verbatim abstract via PubMed 41210042 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.